PET Imaging of Cyclooxygenase-1 in Participants With Neurological Symptoms After COVID-19 Infection Neuro-PASC

What this Trial Is About

Researchers are studying adults aged 18 to 70 years who have neurological symptoms lasting after COVID-19 infection, called Neuro-PASC. The study aims to see if a radioactive tracer called 11CPS13 can detect brain inflammation in these individuals by measuring a biomarker called cyclooxygenase-1 COX-1. The trial also compares these findings to healthy volunteers and evaluates the effect of a treatment called IVIg on participants with Neuro-PASC. All participants will receive the same tests, including blood tests, heart function assessment, MRI scans, and PET scans using the injected tracer 11CPS13. The PET scan involves inserting needles to inject the tracer and draw blood while capturing brain images over about two hours. Neuro-PASC participants will be scanned before and after IVIg treatment to assess changes in brain inflammation. Participants will attend up to five clinic visits over 11 to 14 weeks. Throughout the study, researchers will collect imaging data, blood markers, and clinical test results, including finger-tapping speed and symptom improvement. The main measure is the tracers distribution volume in the brain, assessed over 36 months. Safety is monitored with laboratory and heart tests, and healthy volunteers without active COVID-19 infection are also included for comparison.

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)